Endocare® (Single Care) in Pain-related Endometriosis

Pain Clinical Trial

Official title:

Evaluation of Pain Relief in Patients Experiencing Endometriosis-related Pain and Treated With Endocare®

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04650516
• Other study ID #: 20206-A01541-38
• Status: Completed
• Phase: N/A
• Start date: December 3, 2020
• Est. completion date: May 18, 2021

Study information

• Verified date: August 2021
• Source: Lucine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Endocare® treatment is a stand-alone software medical device, which is composed of a mobile application and an accessory VR headset, intended to mitigate the pain for patients prone to endometriosis.

Description:

Endocare® treatment is a stand-alone software medical device, which is composed of a mobile application and an accessory VR headset, intended to mitigate the pain for patients prone to endometriosis.

Mitigation of pain is realized through sequences of treatments via audio and visual stimulations.

The Endocare® treatment's main functionality, which addressed the intended purpose, is conducting sequences for treatment to mitigate the pain sensed by the patient.

The software will allow mitigating the sensed pain through 3D Virtual Reality via sequences of environments. The software will emit through sequences of 3D environments, auditory and visual stimulations.

The medical device is a CE marked Class I device. Women suffering from endometriosis present recurrent pelvic pain impairing their quality of life. The endometriosis-related pain has pejorative repercussions on sexual, family and professional life. Currently, the physician armamentarium is limited to analgesics and non-steroid anti-inflammatory drugs to treat endometriosis-related pain. Endocare® treatment intends to relieve pain thanks to its action on central nervous system. This study will describe the evolution of pain in patients experiencing endometriosis-related pain after a single treatment of Endocare® or a digital control.

The use of a digital control as a comparator is the only way to show a specific effect of the Endocare® treatment. Therefore, a digital control displaying visual and auditive sequences with no expected effect will be used for the study. This digital control, for which only a placebo effect may occur, will be displayed on a tablet instead of VR (Colloca et al., 2020).

The main analysis will be performed on an intent-to-treat basis. The statistical analysis will be performed using the SAS 9.4 (or higher) software (SAS Institute, Cary, NC, USA).

Continuous variables will be described by the number of observations, mean, standard deviation, minimum, maximum and median. Categorical variables will be described by the number and percentage of each modality. Percentages will be calculated on the number of observed data.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 45
• Est. completion date: May 18, 2021
• Est. primary completion date: May 18, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Woman = 18 years old

• With a diagnosis of endometriosis

• Willing to participate in the study and having signed the informed consent form

• Suffering from a moderate-to-severe endometriosis-related pain = 4 on numerical rating scale (NRS) at the time of inclusion

Exclusion Criteria:

• Pregnant or breastfeeding woman

• Woman having consumed painkillers within 8h prior inclusion

• Woman participating in an interventional study or having participated in an interventional study within the 30 days before enrolment

• Contraindication to Endocare® or digital control: patients with severe visual, hearing and/or cognitive impairments, patients with colour blindness, patients who are photo-sensitive or suffering from epilepsy or motion sickness

• Woman being an employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator

Related Conditions & MeSH terms

• Endometriosis
• Pain

Intervention

Device:
• Virtual reality
20 minutes treatment in virtual reality
• Digital control
20 minutes digital control movie on tablet without virtual reality

Locations

Country	Name	City	State
France	Clinique Tivoli Ducos	Bordeaux	Gironde

Sponsors (1)

Lead Sponsor	Collaborator
Lucine

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean pain intensity 60 minutes after the beginning of treatment	Pain assessment evaluated with numerical rating scale (NRS): Pain assessed by 11-point numerical rating scale (NRS): 0=no pain; 10=unbearable pain	60 minutes after treatment
Secondary	Evaluate the pain evolution after Endocare® compared to the digital control	Pain assessment evaluated with numerical rating scale (NRS): 11-point numerical scale (0=no pain; 10=unbearable pain)	baseline (before treatment), 15 minutes, 30 minutes, 45 minutes, and 240 minutes after treatment
Secondary	Evaluate the pain relief after Endocare ® compared to the digital control	The time to reach and maintain pain relief as assessed by the pain relief score = 3; PRS is a 5-point categorical scale (0: no relief, 1: slight relief, 2: moderate relief, 3: lots of relief and 4: complete relief); The event will be defined by the first occurrence of PRS = 3	15 minutes, 30 minutes, 45 minutes, 60 minutes, 240 minutes after treatment
Secondary	Evaluate the maximum reduction in pain after Endocare® compared to the digital control	The time to reach and maintain pain reduction =30% and =50% evaluated with NRS 11-point numerical scale (0=no pain; 10=unbearable pain)	15 minutes, 30 minutes, 45 minutes, 60 minutes, 240 minutes after treatment
Secondary	Describe the women satisfaction toward Endocare® or the digital control	Satisfaction after using Endocare® compared to the digital control, will be self-rated by the patient on a 7-point Likert scale: 1: extremely dissatisfied, 2: very dissatisfied, 3: rather dissatisfied, 4: neutral, 5: rather satisfied, 6: very satisfied, 7: extremely satisfied	240 minutes after treatment
Secondary	Evaluate the safety of Endocare® or the digital control	Incidence of adverse events (AE)	through study completion, at 240 minutes after treatment